Overview and evidence boundaries
Research procurement is strongest when the buying decision follows a defined scientific question. A catalogue description may help identify a potential material, but it cannot replace laboratory specifications or support promises of a medical outcome. This checklist focuses on documentation and decision-making rather than therapeutic claims.
Define the intended research use
Start with a short written statement of the analytical or experimental question. Identify the properties that matter to that study, such as chemical identity or documented handling conditions. A purchasing decision is easier to defend when each requested specification has an explicit purpose.
The editorial boundary in “A research procurement checklist without treatment promises” matters here. WOLVERINE-labelled empty research glass vials and laboratory supplies catalogue identify laboratory-related goods; neither link is proof of medical authorisation, compound purity or human efficacy.
Record material identity and sample details
A useful record links the product description to a batch or sample identifier and clarifies whether a listing names one compound or a mixture. Teams should distinguish the container label from verified material content. Where key identifiers or test methods are absent, mark the information as unconfirmed.
Ask suppliers questions the evidence can answer
Requests for documentation should be specific: which sample was tested, by whom, using what analytical approach, and on which date? Vague quality assurances cannot answer these questions. A laboratory can then decide which claims need independent confirmation before the material is suitable for the intended project.
Review provenance, transport and end-of-use obligations
Procurement records should include supplier details, receipt condition, relevant handling information and the team responsible for inventory control. The study’s applicable safety and disposal procedures should be established before use. An attractive price or delivery estimate does not offset an unresolved provenance question.
Keep purchasing decisions separate from treatment claims
A laboratory can approve a material for a narrowly defined investigation without concluding that it is safe or effective for people. Documents prepared for procurement should not describe experimental peptides as established treatments. Where clinical questions arise, they belong to qualified healthcare professionals and appropriately designed human research.



